Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Severine Vermeire

Showing results (81-90 of 232) with videos related to

Pageof 24
Sort By:
United European Gastroenterology Journal|August 8, 2018
Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter studyTriana Lobatón, Talat Bessissow, Alexandra Ruiz-Cerulla, et al.
Inflammatory Bowel Diseases|February 10, 2026
Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory DisordersVirginia Solitano, Laurent Peyrin-Biroulet, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|September 10, 2015
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's DiseaseThomas Billiet, Konstantinos Papamichael, Magali de Bruyn, et al.
Inflammatory Bowel Diseases|September 7, 2006
The role of vascular endothelial growth factor (VEGF) in inflammatory bowel diseaseMarc Ferrante, Marie Pierik, Liesbet Henckaerts, et al.
Inflammatory Bowel Diseases|April 16, 2013
Serum adalimumab concentration and clinical remission in patients with Crohn's diseaseYi-Lin Chiu, David T Rubin, Severine Vermeire, et al.
The American Journal of Gastroenterology|March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 StudyScott D Lee, Severine Vermeire, Ryan Ungaro, et al.
Inflammatory Bowel Diseases|July 15, 2010
Seroreactivity against glycolytic enzymes in inflammatory bowel diseaseNathalie Vermeulen, Severine Vermeire, Ingrid Arijs, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2010
Genomic copy number determines functional expression of {beta}-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary diseaseWim Janssens, Hilde Nuytten, Lieven J Dupont, et al.
Inflammatory Bowel Diseases|February 7, 2015
Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective studyLize Bollen, Niels Vande Casteele, Miet Peeters, et al.
International Journal of Inflammation|December 23, 2011
Assessment of the microbiota in microdissected tissues of Crohn's disease patientsGert De Hertogh, Bart Lemmens, Peter Verhasselt, et al.
Pageof 24

Showing results (81-90 of 232) with videos related to

Sort By:
Pageof 24
United European Gastroenterology Journal|August 8, 2018
Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter studyTriana Lobatón, Talat Bessissow, Alexandra Ruiz-Cerulla, et al.
Inflammatory Bowel Diseases|February 10, 2026
Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory DisordersVirginia Solitano, Laurent Peyrin-Biroulet, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|September 10, 2015
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's DiseaseThomas Billiet, Konstantinos Papamichael, Magali de Bruyn, et al.
Inflammatory Bowel Diseases|September 7, 2006
The role of vascular endothelial growth factor (VEGF) in inflammatory bowel diseaseMarc Ferrante, Marie Pierik, Liesbet Henckaerts, et al.
Inflammatory Bowel Diseases|April 16, 2013
Serum adalimumab concentration and clinical remission in patients with Crohn's diseaseYi-Lin Chiu, David T Rubin, Severine Vermeire, et al.
The American Journal of Gastroenterology|March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 StudyScott D Lee, Severine Vermeire, Ryan Ungaro, et al.
Inflammatory Bowel Diseases|July 15, 2010
Seroreactivity against glycolytic enzymes in inflammatory bowel diseaseNathalie Vermeulen, Severine Vermeire, Ingrid Arijs, et al.
American Journal of Respiratory and Critical Care Medicine|April 10, 2010
Genomic copy number determines functional expression of {beta}-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary diseaseWim Janssens, Hilde Nuytten, Lieven J Dupont, et al.
Inflammatory Bowel Diseases|February 7, 2015
Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective studyLize Bollen, Niels Vande Casteele, Miet Peeters, et al.
International Journal of Inflammation|December 23, 2011
Assessment of the microbiota in microdissected tissues of Crohn's disease patientsGert De Hertogh, Bart Lemmens, Peter Verhasselt, et al.
Pageof 24